Trulieve Cannabis Non-GAAP EPS of $0.09 beats by $0.02, revenue of $230M beats by $8.37M
Trulieve Cannabis reported Q3 Non-GAAP EPS of $0.09, beating estimates by $0.02, with revenue of $230M, down 20.1% year-over-year but exceeding expectations by $8.37M. The company also reported strong cash flow from operations and free cash flow for the first nine months of 2026.
How this was made
The 30-second read
Why it matters
The earnings beat may trigger buying interest and short covering, potentially lifting the stock in after‑hours trading.
Market read
First‑report earnings beat for a mid‑cap cannabis stock; likely short‑term price move.
What to watch
Regulatory environment and upcoming state‑level voting could affect future growth.
Background
Trulieve Cannabis is the first NYSE‑listed cannabis company, and its earnings are closely watched by sector investors.
Ticker impact
Trulieve Cannabis reported Q3 Non‑GAAP EPS of $0.09, beating expectations by $0.02 and revenue of $230M, beating by $8.37M.
likely upward pressure as the market prices in the earnings beat.
The beat is fresh primary data; investors typically reward surprise earnings.
Market effects
Positive earnings may lift the broader U.S. cannabis sector.
May boost sentiment for other NYSE‑listed cannabis stocks.
Limited to cannabis investors; no broader macro impact.
Counterpoint
If the beat is driven by one‑off items, the rally could be short‑lived.
Key entities
- CompanyTrulieve Cannabis Corp.
NYSE‑listed cannabis operator reporting Q3 results.
